AccessibilityHelp
Rapid Therapeutic Science Laboratories logo

Rapid Therapeutic Science Laboratories(OTC) RTSL

Market Cap$3.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-100%
5 Year-100%
1 Year-87%
1 Month+0%
$0.00
+0.00%
+0.00Today
Rapid Therapeutic Science Laboratories last closing stock price
MetricPriceDate
Last closeUSD 0.002026-10-19
Rapid Therapeutic Science Laboratories stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-10-06
1 month+0%USD 0.002026-09-09
3 month+300%USD 0.002026-07-14
Year to date-73.33%USD 0.002025-12-31
1 year-86.67%USD 0.002025-10-16
3 year-91.67%USD 0.002023-10-17
5 year-99.99%USD 4.882021-10-20
Since inception-100%USD 13.752014-01-21

Rapid Therapeutic Science Laboratories Financials at a Glance

Market Cap

$3.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

$634.51K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-2.29 (Low)

Price

$0.00

Volume

1

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.01

Estimated Earnings Date

Mar 31, 2023

RTSL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Rapid Therapeutic Science Laboratories

Rapid Therapeutic Science Laboratories, Inc. is a biotechnology firm focused on the innovative aerosolized delivery of non-psychoactive cannabinoids. The company aims to address various health conditions, including chronic pain and PTSD, through its unique product offerings.

Products and Services
  • Pressurized meter dose inhalers (MDIs) for cannabinoid delivery
  • Sublingual oral spray devices for effective absorption
  • Water-soluble CBD and CBG isolates under the "nhaler" brand
Growth Outlook
  • Established in 2013, the company has a solid foundation in the biotechnology sector
  • Innovative product line positions the company for growth in the expanding cannabinoid market
  • Focus on treating chronic conditions aligns with increasing healthcare demands
Financial Highlights
  • Recent quarterly net income reported at -$34,538
  • Trailing twelve months (TTM) revenue remains at $0
  • Current liabilities significantly exceed total assets, indicating financial challenges
Rapid Therapeutic Science Laboratories, Inc. operates in a niche market with a focus on cannabinoid therapies. The company's innovative delivery methods aim to enhance patient outcomes for various health issues. Despite facing financial challenges, the potential for growth in the cannabinoid market remains significant, driven by increasing healthcare needs and a growing acceptance of cannabinoid-based treatments. Investors may find interest in the company's unique approach and its potential to capture market share in this evolving industry.
AI Generated • Oct 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

2

CEO

Donal R. Schmidt, Jr., MBA

Headquarters

De Leon, TX 76444, US

RTSL Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

5.89%

Return on Capital

-22.97%

Return on Assets

-18.94%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

8.83M

Volume

1

Avg. Volume

5.831

Financials (TTM)

Gross Profit

-$5.99K

Operating Income

-$101.54K

EBITDA

-$98.83K

Operating Cash Flow

-$566.60K

Capital Expenditure

-$249.58K

Free Cash Flow

-$816.19K

Cash & ST Invst.

$0.00

Total Debt

$3.45M

Rapid Therapeutic Science Laboratories Performance Analysis

Rapid Therapeutic Science Laboratories annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 534N/A
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
Rapid Therapeutic Science Laboratories sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-12-31N/A
Q12023-03-31N/A
Q22023-06-30N/A
Q42024-12-31N/A
Rapid Therapeutic Science Laboratories annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -0.38N/A
20222022-12-31USD -0.23-38.4%
20232023-12-31USD 0.00N/A
20242024-12-31USD -0.01N/A
Rapid Therapeutic Science Laboratories sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-12-31105.4%
Q12023-03-311755.0%
Q22023-06-30-86.5%
Q42024-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2024YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$5.99K

N/A

Gross Margin

0.00%

N/A

Market Cap

$3.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.17K

N/A

Employees

3

N/A

Net Income

-$34.54K

+94.0%

EBITDA

-$3.39K

+99.0%

Quarterly Fundamentals

Name
Q4 2024YOY CHG

Total Cash

$0.00

N/A

Total Debt

$3.45M

-8.9%

Accounts Receivable

$0.00

N/A

Inventory

$175.05K

+0.0%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$3.45M

+4.0%

Return on Assets

-18.94%

N/A

Return on Invested Capital

2.70%

N/A

Free Cash Flow

-$7.33K

+97.1%

Operating Cash Flow

-$7.33K

+97.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CBDHFHempfusion Wellness Inc.
$0.00+0.00%
NNMXNanomix Corporation
$0.00+0.00%
NWYUNew You, Inc.
$0.00+0.00%
QSAMQSAM Biosciences, Inc.
$8.30-99.95%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$12.35-18.54%
EWZiShares - iShares Msci Brazil ETF
$33.34-21.72%
ITUBItaú Unibanco
$7.56-21.82%
XPXP
$15.68-48.45%

Questions About RTSL

What is the current price of Rapid Therapeutic Science Laboratories?

Rapid Therapeutic Science Laboratories is trading at $0.00 per share.

What is the 52-week range for Rapid Therapeutic Science Laboratories?

Over the past 52 weeks, Rapid Therapeutic Science Laboratories has traded between $0.00 and $0.01.

How much debt does Rapid Therapeutic Science Laboratories have?

As of the most recent reporting period, Rapid Therapeutic Science Laboratories reported total debt of $3.45M.

How much cash does Rapid Therapeutic Science Laboratories have on hand?

Rapid Therapeutic Science Laboratories reported $10.15K in cash and cash equivalents in its most recent financial results.

What is Rapid Therapeutic Science Laboratories’s dividend yield?

Rapid Therapeutic Science Laboratories does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services